Chengdu‑based Kelun‑Biotech announced a Phase 3 victory for its TROP2 antibody‑drug conjugate combined with Merck’s pembrolizumab (Keytruda) in first‑line lung cancer. The company said it will submit the dataset to Chinese regulatory authorities. The outcome brings an ADC‑checkpoint inhibitor combination toward potential approval in China and highlights continued innovation in TROP2‑targeted payload delivery. ADCs attach cytotoxic drugs to antibodies to concentrate killing in tumor cells; combining ADCs with immunotherapy aims to increase tumor antigen release and immune activation.